Pharmacological Management of Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder marked by insulin resistance and progressive β cell dysfunction leading to hyperglycaemia and its complications. Pharmacological management aims to achieve and maintain target glycaemic levels, minimise variability, and reduce cardiovascular and renal risk. Metformin remains the first-line therapy owing to efficacy, safety and potential cardiovascular benefits. In addition, sulfonylureas, thiazolidinediones and meglitinides improve glycaemic control but carry risks of hypoglycaemia and weight gain. Incretin-based therapies, including DPP-4 inhibitors and GLP-1 receptor agonists, enhance glucose-dependent insulin release with modest weight effects and low hypoglycaemia risk. SGLT2 inhibitors promote urinary glucose excretion, imparting reductions in blood pressure and weight alongside renal and cardiovascular protection. Insulin therapy, in basal or intensified regimens, is reserved for inadequate control or advanced β cell failure. An emerging focus is on combination regimens that target complementary pathways to optimise metabolic outcomes, weight profiles and organ protection. Personalisation of therapy considers patient preferences, comorbidities, cost and risk of adverse events, thereby facilitating holistic management across the spectrum of disease severity and related target-organ damage.

Research from Nature Portfolio

Recent meta-analyses have interrogated the efficacy of incretin-based agents and sodium-glucose cotransporter 2 inhibitors in combination. A systematic review of glycaemic variability revealed that DPP-4 inhibitors significantly reduce mean amplitude of glycaemic excursions compared to other oral therapies, highlighting their role in stabilising postprandial glucose swings without elevating hypoglycaemia risk. Another analysis comparing combined SGLT2 inhibitor and DPP-4 inhibitor therapy against DPP-4 inhibitor monotherapy demonstrated superior reductions in glycated haemoglobin, fasting and postprandial glucose, and body weight, with no increased incidence of hypoglycaemia or urinary tract infections, though genital infection risk was modestly elevated. These findings underscore the complementary mechanisms of dual therapy in achieving tighter glycaemic control and weight loss, supporting integrated approaches to pharmacological management.

Pharmacological Management of Type 2 Diabetes Mellitus publication trend

The graph below shows the total number of articles in pharmacological management of type 2 diabetes mellitus across all publications each year (not limited to Nature Index journals).

Technical terms

Insulin resistance: Reduced responsiveness of tissues to insulin signalling, leading to impaired glucose uptake.

β cell dysfunction: Progressive failure of pancreatic β cells to secrete sufficient insulin.

HbA1c (glycated haemoglobin): A biomarker reflecting average blood glucose concentration over approximately three months.

Glycaemic variability: Fluctuations in blood glucose levels characterised by measures such as mean amplitude of glycaemic excursions.

DPP-4 inhibitor: An oral agent that prevents degradation of incretin hormones to augment glucose-dependent insulin secretion.

SGLT2 inhibitor: A class of drugs that block renal glucose reabsorption to increase urinary glucose excretion and lower blood glucose.

GLP-1 receptor agonist: A peptide analogue that mimics glucagon-like peptide-1 to stimulate insulin release and suppress glucagon in a glucose-dependent manner.

Mean amplitude of glycaemic excursions (MAGE): A quantitative metric of the average fluctuations between high and low blood glucose readings.

References

1. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduction and Targeted Therapy (2024).
2. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome (2013).
3. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metabolic Syndrome and Obesity (2021).
4. Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis. Scientific Reports (2019).
5. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Scientific Reports (2018).
6. The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Frontiers in Pharmacology (2022).
7. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovascular Diabetology (2023).